Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

Apostolopoulos, V, Pietersz, G, Tsibanis, A, Drakaki, H, Loveland, B, Plebanski, M, Pouniotis, D, Alexis, M, McKenzie, I and Vassilaros, S 2006, 'Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]', Breast Cancer Research, vol. 18, no. 8, pp. 1-11.


Document type: Journal Article
Collection: Journal Articles

Title Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
Author(s) Apostolopoulos, V
Pietersz, G
Tsibanis, A
Drakaki, H
Loveland, B
Plebanski, M
Pouniotis, D
Alexis, M
McKenzie, I
Vassilaros, S
Year 2006
Journal name Breast Cancer Research
Volume number 18
Issue number 8
Start page 1
End page 11
Total pages 11
Publisher Current Medicine Group Ltd.
Abstract Introduction: Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1. Method: In a randomized, double-blind study, 31 patients with stage II breast cancer and with no evidence of disease received subcutaneous injections of either placebo or oxidized mannan-MUC1, to immunize against MUC1 and prevent cancer reoccurrence/metastases. Twenty-eight patients received the full course of injections of either oxidized mannan-MUC1 or placebo. Survival and immunological assays were assessed. Results: After more than 5.5 years had elapsed since the last patient began treatment (8.5 years from the start of treatment of the first patient), the recurrence rate in patients receiving the placebo was 27% (4/15; the expected rate of recurrence in stage II breast cancer); those receiving immunotherapy had no recurrences (0/16), and this finding was statistically significant (P = 0.0292). Of the patients receiving oxidized mannan-MUC1, nine out of 13 had measurable antibodies to MUC1 and four out of 10 had MUC1-specific T cell responses; none of the placebo-treated patients exhibited an immune response to MUC1. Conclusion: The results suggest that, in early breast cancer, MUC1 immunotherapy is beneficial, and that a larger phase III study should be undertaken.
DOI - identifier 10.1186/bcr1505
ISSN 1465-5411
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 100 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 120 Abstract Views  -  Detailed Statistics
Created: Mon, 06 Dec 2010, 14:11:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us